[Skip to Content]

Upstate Active Clinical Trials

Study Title:

Multi-arm Optimization of Stroke Thrombolysis (MOST): a blinded, randomized controlled
adaptive, multi-arm, adjunctive-thrombolysis efficacy trial in ischemic stroke

What is the purpose of the study?

The MOST study is designed to find out whether adding one of two blood-thinning medicines (argatroban or eptifibatide) to standard treatment helps to decrease the impact of strokes and is safe. Earlier studies have shown that it seems safe and may be helpful to add argatroban or eptifibatide to tPA (standard treatment) to help dissolve clots causing stroke.

Upstate Institutional Review Board (IRB) Number:

1344888

Study Phase:

N/A

Patient Age Group:

Adults

Principal Investigator:

Julius Gene S Latorre

Who can I contact for more information?

Name: Lena F Deb
Phone: 315-464-9756
Email: debl@upstate.edu

Return to Previous Page || Search Again

Top